Leaderna Therapeutics' siRNA Hypertension Drug LDR2402 Enters Phase II Clinical Trial, First of Its Kind in China
Leaderna
Nucleic Acid Drug Developer
Recently,The phase 2 clinical trial application for LDR2402 Injection, a Class 1 new drug independently developed by Leaderna Therapeutics Ltd. (hereinafter referred to as "Leaderna"), has been disclosed on the official website of the Center for Drug Evaluation (CDE) under the National Medical Products Administration.This drug is a small nucleic acid innovative medicine targeting angiotensinogen (AGT) for the treatment of primary hypertension.It is the first siRNA-based antihypertensive drug in China to enter Phase 2 clinical trials.The entry of LDR2402 injection into Phase 2 clinical trials marks a significant breakthrough for Leaderna in the field of small nucleic acid drug research and development, officially moving into a new phase of clinical development.
Source: CDE Official Website
Previously, the Phase 1 clinical trial of LDR2402 Injection conducted by Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital has completed the enrollment of all subjects and single-dose administration. This study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) characteristics of LDR2402 in healthy Chinese subjects and patients with mild hypertension. To date, data from the post-single-dose stage indicate that LDR2402 demonstrates excellent safety.
Currently, LDR2402 Injection has officially entered Phase 2 clinical trials, led by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, in collaboration with multiple research centers across China. The Phase 2 study will focus on exploring the safety, PD characteristics, and preliminary antihypertensive efficacy under multiple dosing regimens, aiming to further validate its therapeutic potential as the first siRNA-based antihypertensive drug in China to enter Phase 2 clinical trials.
About LDR2402
LDR2402 Injection is an RNA interference-based（RNAi）The newly developed small nucleic acid drug through technical development significantly reduced angiotensinogen in preclinical experiments.（AGT）The level can last for more than 6 months after a single injection. AGT is the source of the renin-angiotensin-aldosterone system (RAAS) mechanism. LDR2402 selectively enters the liver, silencing the expression of AGT at its source to achieve blood pressure reduction. In clinical treatment, LDR2402 may improve patient compliance by extending the dosing interval (once per quarter or every six months). It also provides steady blood pressure reduction within 24 hours, reduces blood pressure variability (BPV), and offers greater cardiovascular benefits to patients with hypertension.
About Leaderna
Leaderna Therapeutics Ltd. (成都先衍生物技术有限公司) is a biotechnology company co-founded by former senior executives of listed companies and overseas high-level talents. Officially established in 2022, the company focuses on core technology innovation and new drug development related to oligonucleotides, assembling a high-level R&D team. Leaderna has built a small nucleic acid new drug pipeline in chronic disease areas such as metabolism and cardiovascular/cerebrovascular diseases, aiming to develop small nucleic acid drugs with potential Best-in-Class or First-in-Class qualities.
Part of WinX Capital's Successful Transactions
Biopharmaceuticals:Leadena PharmaceuticalsTongrui BiologicsCanSino BiologicsHaiChuang PharmaGreen Bamboo BiotechHomologous HealthLeadernaHuiSheng BioNeuShen TherapeuticsAidu BioViva BioJinlan GeneQiyue BioChangxi PharmaQingpu BioHealSource BioSuiKun IntelligenceNolead BiotechRed Cloud BiotechComplife BiotechTianchen BiotechBioRayZedmanYinuo PharmaceuticalsQuality Peptide BioEnze TaikangArthur PharmaceuticalsYoujia BiotechSaiyuan BiotechnologyBoin BiotechZhongyin TechnologyPurigin BiotechSpectrum BiotechHuaten PharmaceuticalBioinnoWuJiaHe Gene
Biomanufacturing&Agrifood Technology：Junhe AllianceMethuselahTsingke BiotechLipho BiotechChengyuan BioMeibioBaiKuiRui BioRongrui TechnologyDermina TechHuahao ZhongtianBoruidaQihesheng ScienceGreenonDingchi BioHuapai BiotechBlue Beauty Co., Ltd.AidijingJiawo HuanxianJiawo BlueberryJiawei Da Bio
